A5046973467- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Mycobacterium research and diagnosis
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Renal and related cancers
- Medical Imaging and Pathology Studies
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Microtubule and mitosis dynamics
- Tuberculosis Research and Epidemiology
- Immune cells in cancer
- Mitochondrial Function and Pathology
- Epigenetics and DNA Methylation
- Cancer Cells and Metastasis
- NF-κB Signaling Pathways
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- ATP Synthase and ATPases Research
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Erythrocyte Function and Pathophysiology
The University of Texas MD Anderson Cancer Center
2014-2023
University of Alabama at Birmingham
2009-2017
University of Kansas
2013
The University of Kansas Cancer Center
2013
University of Kansas Medical Center
2013
University of Alabama
2013
Thoracic Surgery Foundation
2009
Institute of Cell Biology
2006
University of Tennessee at Knoxville
2005
Abstract KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine efficacy PD-1 inhibitors these subgroups. Objective response rates to blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) (P < 0.001) Stand Up To Cancer (SU2C) cohort (174 patients) with LUAC patients treated nivolumab CheckMate-057 phase III...
Abstract STK11/LKB1 is among the most commonly inactivated tumor suppressors in non–small cell lung cancer (NSCLC), especially tumors harboring KRAS mutations. Many oncogenes promote immune escape, undermining effectiveness of immunotherapies, but it unclear whether inactivation suppressor genes, such as STK11/LKB1, exerts similar effects. In this study, we investigated consequences loss on microenvironment a mouse model KRAS-driven NSCLC. Genetic ablation resulted accumulation neutrophils...
Abstract Purpose: Promising results in the treatment of non–small cell lung cancer (NSCLC) have been seen with agents targeting immune checkpoints, such as programmed death 1 (PD-1) or ligand-1 (PD-L1). However, only a select group patients respond to these interventions. The identification biomarkers that predict clinical benefit checkpoint blockade is critical successful translation agents. Methods: We conducted an integrated analysis three independent large datasets, including Cancer...
Abstract Cancer cells tend to utilize aerobic glycolysis even under normoxic conditions, commonly called the “Warburg effect.” Aerobic often directly correlates with malignancy, but its purpose, if any, in metastasis remains unclear. When wild-type KISS1 suppressor is expressed, decreases and oxidative phosphorylation predominates. However, when missing secretion signal peptide (ΔSS), invasion are no longer suppressed continue metabolize using glycolysis. KISS1-expressing have 30% 50% more...
9016 Background: Identification of molecular predictors response to PD-1/PD-L1 inhibitors is critical in order maximize their therapeutic potential. We previously reported that KRAS-mutant lung adenocarcinomas (LUAC) with co-occurring genetic events STK11/LKB1(KL) or TP53 (KP) define subgroups marked differences immune contexture, including a paucity CD8+ TILs KL LUAC. Here, we assess clinical responses therapy and KP subsets, data assembled under the auspices SU2C/ACS Lung Cancer Dream...
HIV-1 infection is associated with an early and profound depletion of mucosal memory CD4+ T cells, a population that plays indispensable role in the regulation isotype switching transepithelial transport antibodies. In this study, we addressed whether cell HIV-1-infected individuals results altered humoral responses specific to antigens encountered at surfaces. Comprehensive protein microarray systemic intestinal microbiota demonstrated reduced IgG derived from Proteobacteria Firmicutes but...
3018 Background: Programmed cell death 1 (PD-1) and its ligand PD-L1 have emerged as a critical inhibitory pathway that maintains immune suppression in the tumor microenvironment. Patients with non-small-cell lung cancer (NSCLC) responded to PD-1/PD-L1 blockade, indicating crucial role of NSCLC. It is imperative understand features NSCLC identify biomarkers select which patients may benefit from checkpoint blockade. Epithelial-mesenchymal transition (EMT) key process driving metastasis. Our...
Abstract The fate of dendritic cells (DCs) after Ag presentation may be DC subset-specific and controlled by many factors. role activation-induced apoptosis in regulating function is not clear. We investigated the cutaneous DCs (cDCs), specifically Langerhans (LCs), observed that they undergo successful to CD4 T cells. Caspase-specific inhibitors revealed LC lines use a type II pathway response In support this, BH3-interacting domain (Bid) protein was present at high levels cleaved presence...
Harnessing the ability of cytotoxic T lymphocytes (CTLs) to recognize and eradicate tumor or pathogen-infected cells is a critical goal modern immune-based therapies. Although multiple immunization strategies efficiently induce high levels antigen-specific CTLs, initial increase typically followed by rapid contraction phase resulting in sharp decline frequency functional CTLs. We describe novel approach immunotherapy based on transplantation low numbers antigen-expressing hematopoietic stem...
11002 Background: Little is currently known about how the oncogenotype of LUAC shapes its immune micro-environment. We recently identified that major subsets KRAS-mutant defined on basis co-occurring genomic alterations in STK11/LKB1, TP53 and CDKN2A/B display distinct profiles. Specifically, inactivation LKB1 tumor suppressor associated with striking lack system engagement. Here, we systematically assess contexture LUACs context inactivation. Methods: Our datasets include 431 from TCGA...
e20099 Background: Small cell lung cancer (SCLC) is an aggressive form of characterized by loss the tumor suppressor Rb. Chemotherapy and radiation remain standard care for SCLC patients but produces severe myelosuppression. Cyclin dependent kinases 4 6 (CDK4/6) phosphorylate Rb protein promoting proliferation allowing cells to progress through S phase. We hypothesize that CDK4/6 inhibition a G1 cycle arrest wild type immune fibroblasts resulting in resistance chemotherapy/radiation damage...
Studies of the Pacific, No. 4. Fijian Frontier, by Laura Thompson, with an introduction B. Malinowski. Pp. xxiii, 153. American Council, Institute Pacific Relations, 1940. $2.00. The Discovery New Zealand. By J. C. Beaglehole. xx, 160, plates. Wellington, Department Internal Affairs, 1939. Exploration W. G. McClymont. vii, 202, illus. 5/‐ net. Life Sir Samuel Griffith. A. Douglas Graham. 105. Powells & Pughs Pty.Ltd., Brisbane, I.P.R. Inquiry Series. Australia's Interests and Policies in Far...
3030 Background: Promising results in the treatment of NSCLC have been seen with agents targeting immune checkpoints, such as programmed cell death 1 (PD-1) or ligand (PD-L1). However, only a select group patients respond to these interventions. The identification biomarkers that predict clinical benefit checkpoint blockade is critical successful translation agents. Epithelial-mesenchymal transition (EMT) key process driving metastasis and drug resistance. Previously we developed robust EMT...
Abstract Background: We recently have reported that co-mutations within KRAS-mutated lung adenocarcinoma (LUAD) define a distinct biological phenotype and may offer insights into therapeutic targeting using this classification system. The analysis revealed striking differences in checkpoint ligand expression T cell infiltration between TP53 STK11 (LKB1) co-mutated KRAS LUAD. We, therefore, hypothesized loss of LKB1promotes an immune-suppressed To test this, we analyzed 100 immune-related...